U.S. FDA

Summary : – Expands Blueprint Medicines’ lung cancer pipeline with LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion…

Synopsis: -The FDA recommended Takeda run an additional clinical study to resolve its questions around Eohilia, an oral suspension formulation of the…

Synopsis: CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as…

SYNOPSIS: Takeda announced that U.S. FDA Approved LIVTENCITY (Maribavir) as the First and Only Treatment for People Ages 12 or older and…